王辉;李在村;赵红心;孙丽君;赵清霞;何盛华;刘水青;蔡卫平;李凌华;沈银忠;李惠琴;郭彩萍;吕玮;陈耀凯;宋玉霞;张福杰;

• 1:深圳市第三人民医院/南方科技大学附属第二医院
• 2:首都医科大学北京佑安医院
• 3:首都医科大学北京地坛医院
• 4:郑州市第六人民医院

摘要(Abstract)：

近年来,越来越多的二联简化治疗方案不断涌现,在为临床医生提供更多的治疗选择的同时,也给规范简化治疗带来了挑战。中国性病艾滋病防治协会临床治疗学组制定了《人类免疫缺陷病毒(HIV)抗病毒治疗二联简化疗法专家共识》。此共识是基于国际上最新的相关临床研究数据、指南以及我国的临床应用实践来进行编写,就不同情况下的二联方案的选择和适用条件做出总结,为临床医护人员提供参考与指导。

关键词(KeyWords)： 人类免疫缺陷病毒;简化治疗;两药治疗;稳定转换;治疗共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 王辉;李在村;赵红心;孙丽君;赵清霞;何盛华;刘水青;蔡卫平;李凌华;沈银忠;李惠琴;郭彩萍;吕玮;陈耀凯;宋玉霞;张福杰;

DOI: 10.13419/j.cnki.aids.2020.03.30

参考文献(References)：

• [1]Gueler A,Moser A,Calmy A,et al.Life expectancy in HIV-positive persons in Switzerland:matched comparison with general population[J].AIDS,2017(31):427-436.
• [2]Fernandez-Montero JV,Eugenia E,Barreiro P,et al.Antiretroviral drug-related toxicities-clinical spectrum,prevention,and management[J].Expert Opin Drug Saf,2013(12):697-707.
• [3]Burgess MJ,Zeuli JD,Kasten MJ.Management of HIV/AIDS in older patientsdrug/drug interactions and adherence to antiretroviral therapy[J].HIV AIDS(Auckl),2015(7):251-264.
• [4]Girouard MP,Sax PE,Parker RA,et al.The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States[J].Clin Infect Dis,2016(62):784-791.
• [5]Podzamczer D,Imaz A.Dual antiretroviral therapy:finding a place in the battle[J].Lancet HIV,2016(3):e335-e336.
• [6]Rossetti B,Montagnani F,De Luca A.Current and emerging two-drug approaches for HIV-1 therapy in ART-naive and ART-experienced,virologically suppressed patients[J].Expert Opin Pharmacother,2018(19):713-738.
• [7]DHHS.Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV[EB/OL].(2019)[2020-02-25].https://aidsinfo.nih.gov/guidelines2019.
• [8]EACS.the European Guidelines for the treatment of HIV-positive adults in Europe(version 10.0).[EB/OL].(2019)[2020-02-25].https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.htm L2019.
• [9]中华医学会感染病学分会艾滋病丙肝学组.中国艾滋病诊疗指南(2018版)[J].中国艾滋病性病,2018,24(12):1266-1282.
• [10]Saag MS,Benson CA,Gandhi RT,et al.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults:2018 Recommendations of the International Antiviral Society-USA Panel[J].JAMA,2018(320):379-396.
• [11]Antinori A,Di Biagio A,Marcotullio S,et al.Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.Update 2016[J].New Microbiol,2017(40):86-98.
• [12]Diseases ASGot SSo I,Clinical M,the National AP.Executive summary of the Ge SIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus(updated January 2018)[J].Enferm Infecc Microbiol Clin,2019(37):195-202.
• [13]Katlama C,Ghosn J,Murphy RL.Individualized antiretroviral therapeutic approaches:less can be more[J].AIDS,2017(31):1065-1071.
• [14]Cahn P,Madero JS,Arribas JR,et al.Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection:96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials[J].JAIDS Journal of Acquired Immune Deficiency Syndromes,2020,83(3):310-318.
• [15]Cahn P,Madero JS,Arribas JR,et al.Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection(GEMINI-1 and GEMINI-2):week 48 results from two multicentre,double-blind,randomised,non-inferiority,phase 3 trials[J].Lancet,2019(393):143-155.
• [16]Cahn P,Andrade-Villanueva J,Arribas JR,et al.Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection:48 week results of the randomised,open label,noninferiority GARDEL trial[J].The Lancet Infectious Diseases,2014,14(7):572-580.
• [17]Li L,He H,Lan Y,et al.Dual therapy with lopinavir/ritonavir plus lamivudine could be a viable alternative for antiretroviral-therapy-naive adults with HIV-1 infection regardless of HIV viral load or subgenotype in resource-limited settings:A randomised,open-label and non-inferiority study from China[J].Indian J Med Microbiol,2018(36):513-516.
• [18]Figueroa M,Sued O,Gun A,et al.DRV/R FDC plus 3TC for HIV-1 treatment naive patients:Week 48 results of the ANDES study[J].CROI conference,2018.(Epub ahead of print).
• [19]Bedimo RJ,Drechsler H,Jain M,et al.The RADAR study:week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients.Impact on bone health[J].PLo S One,2014(9):e106221.
• [20]Winston A,Stohr W,Antinori A,et al.Changes in Cognitive Function Over96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine:A Substudy of the NEAT001/ANRS143Trial[J].J Acquir Immune Defic Syndr,2017(74):185-192.
• [21]Reynes J,Trinh R,Pulido F,et al.Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects:96-week results of the PROGRESS study[J].AIDS Res Hum Retroviruses,2013(29):256-265.
• [22]van Wyk J,Ajana F,Bisshop F,et al.Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three-or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1:Phase 3,Randomized,Non-inferiority TANGOStudy[J].Clinical Infectious Diseases,2020.(Epub ahead of print).
• [23]Llibre JM,Hung CC,Brinson C,et al.Efficacy,safety,and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1:phase 3,randomised,non-inferiority SWORD-1 and SWORD-2studies[J].Lancet,2018(391):839-849.
• [24]Aboud M,Orkin C,Podzamczer D,et al.Efficacy and safety of dolutegravirrilpivirine for maintenance of virological suppression in adults with HIV-1:100-week data from the randomised,open-label,phase 3 SWORD-1 and SWORD-2studies[J].The Lancet HIV,2019,6(9):e576-e587.
• [25]Pulido F,Ribera E,Lagarde M,et al.Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression:Randomized,Open-Label,Noninferiority DUAL-GESIDA 8014-RIS-EST45Trial[J].Clin Infect Dis,2017(65):2112-2118.
• [26]Perez-Molina JA,Rubio R,Rivero A,et al.Simplification to dual therapy(atazanavir/ritonavir+lamivudine)versus standard triple therapy[atazanavir/ritonavir+two nucleos(t)ides]in virologically stable patients on antiretroviral therapy:96 week results from an open-label,non-inferiority,randomized clinical trial(SALT study)[J].J Antimicrob Chemother,2017(72):246-253.
• [27]Arribas JR,Girard PM,Landman R,et al.Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression(OLE):a randomised,open-label,noninferiority trial[J].Lancet Infect Dis,2015(15):785-792.
• [28]Maggiolo F,Di Filippo E,Valenti D,et al.NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects:Results of a Controlled,Randomized Trial(Probe)[J].J Acquir Immune Defic Syndr,2016(72):46-51.
• [29]WHO.Update ofrecommendationson first-andsecond-lineantiretroviralregimens[EB/OL].(2019)[2020-02-25].https://www.who.int/hiv/pub/arv/arv-update-2019-policy/en/2019.
• [30]Navarro J,Santos JR,Silva A,et al.Effectiveness of once/day dolutegravir plus boosted darunavir as a switch strategy in heavily treated patients with human immunodeficiency virus[J].Pharmacotherapy:The Journal of Human Pharmacology and Drug Therapy,2019,39(4):501-507.
• [31]Jab?onowska E,Siwak E,Boci?ga-Jasik M,et al.Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients[J].PLo S One,2019(14):1.
• [32]van Lunzen J,Pozniak A,Gatell JM,et al.Brief Report:Switch to RitonavirBoosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection:A Randomized Pilot Study[J].J Acquir Immune Defic Syndr,2016(71):538-543.
• [33]Pett SL,Amin J,Horban A,et al.Maraviroc,as a Switch Option,in HIV-1-infected Individuals With Stable,Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen:Week 48Results of the Randomized,Multicenter MARCH Study[J].Clin Infect Dis,2016(63):122-132.
• [34]Katlama C,Assoumou L,Valantin MA,et al.Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy:results from the ROCn RAL ANRS 157 study[J].J Antimicrob Chemother,2014(69):1648-1652.
• [35]Cheung CY,Wong KM,Lee MP,et al.Prevalence of chronic kidney disease in Chinese HIV-infected patients[J].Nephrol Dial Transplant,2007(22):3186-3190.
• [36]Cao Y,Han Y,Xie J,et al.Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals:a prospective,multicenter study[J].BMC Infect Dis,2013(13):301.
• [37]Brown TT,Qaqish RB.Antiretroviral therapy and the prevalence of osteopenia and osteoporosis:a meta-analytic review[J].AIDS,2006(20):2165-2174.
• [38]Bowman E,Funderburg NT.Lipidome abnormalities and cardiovascular disease risk in HIV infection[J].Current HIV/AIDS Reports,2019,16(3):214-223.
• [39]Postorino MC,Quiros-Roldan E,Maggiolo F,et al.Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate,Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir(ATV/r)to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function[J].Open AIDS J,2016(10):136-143.
• [40]Randell P,Jackson A,Milinkovic A,et al.An open-label,randomized study of the impact on insulin sensitivity,lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers[J].Antivir Ther,2017(22):145-151.
• [41]Zash R,Holmes L,Diseko M,et al.Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana[J].N Engl J Med,2019(381):827-840.